Objective measurement of parasympathetic function as measured by 24-hour heart rate variability improved in the active group compared with placebo. Ease of falling asleep, awakenings, and am grogginess improved. The difference between the active and placebo groups was significant (P = 0.01). In the placebo group, the baseline sleep duration was 7.17 +/- 7.6 compared with 7.11 +/- 3.67 after placebo (P = nonsignificant, n = 9).
In the active group, the baseline duration of sleep was 5.0 hours (mean), whereas after Gabadone, the duration of sleep increased to 6.83 (P = 0.01, n = 9). The difference was statistically significant (P = 0.02). In the placebo group, the baseline latency time was 34.8 minutes compared with 33.1 minutes after placebo (P = nonsignificant, n = 9). In the active group, the baseline time to fall asleep was 32.3 minutes, which was reduced to 19.1 after Gabadone administration (P = 0.01, n = 9). Autonomic nervous system function was measured by heart rate variability analysis using 24-hour electrocardiographic recordings.
Sleep quality was measured using a visual analog scale. Sleep latency and duration of sleep were measured by daily questionnaires. Eighteen patients with sleep disorders were randomized to either placebo or active treatment group.
Alpha waves 9 hours trial#
This study was an outpatient, randomized, double-blind, placebo-controlled trial of a combination amino acid formula (Gabadone) in patients with sleep disorders.
0 kommentar(er)
